Factors that influence prescribers in their selection and use of COX-2 selective inhibitors as opposed to non-selective NSAIDs*

Pharmacy World and Science

Volumn 27, Issue 4, 2005, Pages 316-320

  Gunnarsdóttir, Anna I ^a   Kinnear, Moira ^b,c  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b Lothian Pharmacy Practice Unit   (United Kingdom)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Case series; COX 2 selective inhibitors; Medical decision making; Non steroidal anti inflammatory drugs (NSAIDs); Prescribing; Questionnaire; Scotland

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CONTROLLED STUDY; DRUG FORMULARY; DRUG INDUSTRY; DRUG SCREENING; DYSPEPSIA; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TOXICITY; GENERAL PRACTITIONER; GEOGRAPHY; HUMAN; NORMAL HUMAN; PEPTIC ULCER; PRESCRIPTION; QUESTIONNAIRE; SMOKING; UNITED KINGDOM;

AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DECISION MAKING; DRUG UTILIZATION; FORMULARIES; GASTROINTESTINAL DISEASES; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; QUESTIONNAIRES; SCOTLAND;

EID: 26844512087     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-005-2454-x     Document Type: Article

References (29)

1. WW. Bolten 1998 Scientific rationale for specific inhibition of COX-2 J Rheumatol 51 25 suppl 2 7
2. SE Gabriel L Jaakkimainen C. Bombardier 1991 Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs Ann Intern Med 115 787 96
3. AL Blower A Brooks GC Fenn A Hills MY Pearce S Morant 1997 Emergency admissions for upper gastrointestinal disease and their relation to NSAID use Aliment Pharmacol Ther 11 283 91
4. JM Seager CJ. Hawkey 2001 ABC of the upper gastrointestinal tract: indigestion and non-steroidal anti-inflammatory drugs BMJ 323 1236 9
5. PE. Lipsky 2001 Introduction Am J Med 110 3A 1S 2S
6. M Teeling K Bennett J. Feely 2004 Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Br J Clin Pharmacol 57 337 43
7. National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. Technology appraisal guidance-no.27 July 2001. http://www.nice.org.uk (March 2003).
8. K Aström C Duggan I. Bates 2002 Influences on prescribing: the perception of general practitioners in two primary care trusts Int J Pharm Pract 10(suppl) R10
9. J Avorn M Chen R. Hartley 1982 Scientific versus commercial sources of influence on the prescribing behaviour of physicians Am J Med 73 4 8
10. PE Green VR. Rao 1971 Conjoint measurement for quantifying judgmental data J Marketing Res 8 355 63
11. M Van der Pol M. Ryan 1995 Methodological issues involved in carrying out a conjoint analysis study: an application to consumer preferences for fruit and vegetables Health. Economics Research Unit Discussion paper no 04/95 University of Aberdeen Aberdeen
12. M Ryan J. Hughes 1995 Using conjoint analysis to value surgical versus medical management of miscarriage. Health Economics Research Unit Discussion paper no 06/95 University of Aberdeen Aberdeen
13. The Lothian Joint Formulary: overcoming the barriers to formulary success. Pharmacy in Practice September 2002;279-84
14. The Lothian Joint Formulary. Drugs used in rheumatic diseases and gout (chapter 10.1). National Health Service (NHS) Lothian. http://www.ljf.scot.nhs. uk (December 2004).
15. WM Strull B Lo G. Charles 1984 Do patients want to participate in medical decision making ? JAMA 252 2990 4
16. A. Wazana 2000 Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 283 373 80
17. D. McCarthy 1998 Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definition and epidemiology Am J Med 105 5A 3S 9S
18. G Singh D. Rosen Ramey 1998 NSAID induced gastrointestinal complications: the ARAMIS perspective-1997 J Rheumatol Suppl. 51 8 16
19. R. Stalnikowicz-Darvazi 1995 Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events J Clin Gastroenterol 21 13 6
20. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. for the VIGOR study group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. NEJM 2000; 343: 1520-8.
21. EF Silverstein G Faich JL Goldstein LS Simon T Pincus A Whelton 2000 Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study JAMA 284 1247 55
22. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, McGowan J. Prevention of NSAID induced gastroduodenal ulcers. The Cochrane Database of Systematic Reviews, Issue 4, 2004.
23. L Hooper TJ Brown RA Elliott K Payne C Roberts D. Symmons 2004 The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review BMJ 329 948 52
24. M. Ryan 1999 A role for conjoint analysis in technology assessment in health care Int J of Technol Assess Health Care 15 443 57
25. MC Weiss D. Scott 2000 Clinical decision making- an application of judgement analysis and its potential for pharmacy Int J Pharm Pract 8 33 41
26. M Ryan S. Farrar 2000 Using conjoint analysis to elicit preferences for health care BMJ 320 1530 3
27. Pearmain D, Swanson J, Kroes E, Bradley M. Stated Preferences Technique. A Guide To Practice (2nd edition). Steer Davies Gleave and Hague Consulting Group, 1991.
28. P Edwards I Roberts M Clarke C DiGuiseppi S Pratap R Wentz 2002 Increasing response rates to postal questionnaires: systematic review BMJ 321 1 9
29. Medicines management team. Survey results and new COX-2 guidelines. Lothian Prescrib Bull 2003; 5:1.